Nath Bio-Genes (India) Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 5 Aug 2026 | Agricultural Food & other Products | Market Cap: ₹313 Cr
Future growth expectations for Nath Bio-Genes (India) Limited: - Targeting around 15% top-line growth over last year for H2 FY '26 (Devinder Khurana). Management expects around 15% revenue growth over the previous year for FY '26, with an aspirational target of reaching INR 500 crores revenue next year (FY '27), implying 15-20% growth potential.
From Nath Bio-Genes (India) Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹153
Market Cap
₹313 Cr
P/E Ratio
9.2
How does Nath Bio-Genes (India) Ltd rank in Agricultural Food & other Products?
Compare Nath Bio-Genes (India) Ltd against every Agricultural Food & other Products company this quarter on revenue, margins and earnings-call signals.
Nath Bio-Genes (India) Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹52 Cr, net profit ₹0 Cr.
Full financials →📊 Revenue & Sales Performance
📈 Profitability & Margins
- →Management expects around 15% revenue growth over the previous year for FY '26, with an aspirational target of reaching INR 500 crores revenue next year (FY '27), implying 15-20% growth potential.
- →Bottom line expected to improve accordingly; if revenue hits INR 500 crores, bottom line could be approximately INR 100 crores, improving EPS and intrinsic value of shares.
- →EBITDA margins have slightly decreased due to higher credit extended to customers but expected to improve once the market stabilizes and credit sales reduce.
- →Management plans continued operational improvements and R&D investments to drive product acceptance and market share, supporting sustained growth.
- →Dividend payouts have been consistent and are expected to increase if profits improve.
- →Overall, management is confident of better operating and net profit margins with a steady year-on-year growth trajectory in coming years.
🏗️ Capital Expenditure Plans
- →No new capital investment is being made currently in the Philippines as government permissions are pending; only time and energy are being invested to secure approvals (Page 17).
- →The company is focusing on research and development (R&D) with increased investments to develop superior and innovative products; significant product registration efforts are ongoing under the Plant Varieties Protection Act (Pages 14 and 7).
- →There is no plan to sell Aurangabad land; it will continue to be used for seed cultivation and retained as a valued asset (Page 14).
- →A strategic focus remains on developing and launching new products across segments over the next 3-4 years to drive growth (Page 7).
- →The Uzbekistan joint venture is progressing with product evaluation, parallel seed production, and building a marketing structure (Page 14).
- →No explicit mention of large-scale future capex targets or investments beyond these ongoing efforts was provided.
💰 Fundraising & Capital Structure
📋 Order Book & Pipeline
- →As of the conference call dated November 14, 2025, Nath Bio-Genes did not explicitly state the exact current order book or pending orders.
- →However, it was mentioned that there is around INR 100 crores of advanced booking lying in their books, yet to be adjusted against receivables.
- →The company expects that these advanced bookings, along with recoveries from the market, will reduce debtor levels.
- →Stock levels accumulated this year are expected to be either maintained or slightly increased, manageable for Kharif 2026 sales.
- →Overall, the company is prepared for demand in upcoming seasons, with product sales anticipated to grow, supported by ongoing operational improvements and product acceptance by farmers.
Key Metrics
Frequently Asked Questions
What were Nath Bio-Genes (India) Ltd Q2 FY26 results?
Future growth expectations for Nath Bio-Genes (India) Limited: - Targeting around 15% top-line growth over last year for H2 FY '26 (Devinder Khurana). Management expects around 15% revenue growth over the previous year for FY '26, with an aspirational target of reaching INR 500 crores revenue next year (FY '27), implying 15-20% growth potential.
What is Nath Bio-Genes (India) Ltd share price analysis?
Nath Bio-Genes (India) Ltd currently shows a neutral. The stock trades at a P/E of 9.2 with a market cap of ₹313 Cr. Investors should review the full earnings analysis for detailed insights.
Is Nath Bio-Genes (India) Ltd planning capital expenditure?
No new capital investment is being made currently in the Philippines as government permissions are pending; only time and energy are being invested to secure approvals (Page 17).
Keep Nath Bio-Genes (India) Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.